AI in drug discovery

News

Bioptimus raises $41m for its GenAI model for biology

AI startup Bioptimus takes its funding above $76m as it prepares for the launch of a universal foundation model for pathology later this year.

News

AMD shadows NVIDIA with a move into AI drug discovery

Chipmaker AMD has taken a 20% stake in Absci, a specialist in the use of artificial intelligence in for biologic drug discovery.

News

Novo Nordisk swells alliance with AI firm Valo Health

Novo Nordisk almost doubles the scale of its R&D alliance with AI specialist Valo Health, which now spans 20 programmes and a value of up to $4.6bn.

News

Valo Health chief executive Brian Alexander, who is also CEO-Partner of Flagship Pioneering

Flagship-backed AI startup Valo shelves eye disease drug

Valo Health will no longer develop its ROCK1/2 inhibitor for diabetic retinopathy on its own after a trial readout but will seek to partner the drug.

R&D

The AI revolution in pharma

The pharmaceutical industry is at a pivotal moment. Artificial intelligence (AI) is shifting from improving processes to reshaping disease treatment and care delivery.

News

Mulvany hits the reset button at BenevolentAI

The shape of BenevolentAI following the return of co-founder Ken Mulvany has started to crystallise and could see the company return to private hands.

Bioptimus raises $41m for its GenAI model for biology

AMD shadows NVIDIA with a move into AI drug discovery

Novo Nordisk swells alliance with AI firm Valo Health

Flagship-backed AI startup Valo shelves eye disease drug

The AI revolution in pharma

Mulvany hits the reset button at BenevolentAI

Precision Neuro breaks new ground in BCI technology

Discover a new era of healthcare panel engagement: Grounded ...

AI in drug discovery

Editor's Picks